Partner Therapeutics, INC.
UEI J33MSDBJZMC6 · MA · SAM.gov record ↗
$39.1M
FY2025 obligations
4
Contract awards
Aug 15, 2023
First action
Sep 8, 2025
Latest action
Obligations by agency
- Department Of Health And Human Services$39.1M
- Department Of Veterans Affairs$0
Obligations by NAICS
Monthly obligations
Oct 24
Nov 24
Feb 25
Mar 25
May 25
Aug 25
Sep 25
Contracts ending within 18 months (recompete watch)
| PIID | Description | Agency | NAICS | Obligated | Start | End |
|---|---|---|---|---|---|---|
| 75A50323F80027 ↗ | LEUKINE 250MCG VIL INJ (5PKG) | Office Of Assistant Secretary For Preparedness And Response | 325412 | $39.1M | Sep 26, 2023 | Sep 29, 2026 |
Largest awards
| PIID | Description | Agency | NAICS | Obligated | Start | End |
|---|---|---|---|---|---|---|
| 75A50323F80027 ↗ | LEUKINE 250MCG VIL INJ (5PKG) | Office Of Assistant Secretary For Preparedness And Response | 325412 | $39.1M | Sep 26, 2023 | Sep 29, 2026 |
| 75A50123C00064 ↗ | R&D FOR REPURPOSING FX06, A HOST-DIRECTED THERAPY, FOR TREATMENT OF SEVERE DISEASE IN PATIENTS WITH SUDAN VIRUS DISEASE (SVD) OR OTHER FILOVIRUSES AOI #22 REBOOT | Office Of Assistant Secretary For Preparedness And Response | 541714 | $0 | Sep 25, 2023 | Jan 30, 2026 |
| 75A50124C00061 ↗ | PARTNER THERAPEUTICS: THE OVERALL OBJECTIVE OF THIS CONTRACT IS TO CONFIRM LEUKINE SAFETY IN SEPSIS PATIENTS, INFORM OPTIMAL LEUKINE DOSING, EXPLORE LEUKINE EFFICACY, AS WELL AS ADVANCE DEVELOPMENT OF MONOCYTE HUMAN LEUKOCYTE ANTIGEN-DR (MHLA-DR) AS | Office Of Assistant Secretary For Preparedness And Response | 541715 | $0 | Sep 30, 2024 | Mar 31, 2028 |
| 36F79723D0171 ↗ | 2025 PUBLIC LAW PRICING UPDATES | Department Of Veterans Affairs | 325412 | $0 | Aug 15, 2023 | — |